Please assess the completion status of the following clinical trial:

Trial Title: 2-5 Intermittent Caloric Restriction in HIV

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
-INCLUSION CRITERIA:~1. Aged 18 to 65 years~2. HIV RNA level less than or equal to 200 copies/mL for greater than or equal to1 year (1 measure greater than or equal to 200 allowed if also \<500 and preceded and followed by one or more undetectable values)~3. Cluster of differentiation 4 (CD4) \>200 cells/mL and no active opportunistic infection or malignancy~4. BMI greater than or equal to 30 kg/m\^2~5. One or more components of the metabolic syndrome as defined below.~   * Risk Factor: Waist circumference~     * Men: Defining Level: \>102 cm~    * Women: Defining Level: \>88 cm~  * Risk Factor: Triglycerides, greater than or equal to 150 mg/dL~  * Risk Factor: High density lipoprotein (HDL) cholesterol~     * Men: Defining Level: \<40 mg/dL~    * Women: Defining Level: \<50 mg/dL~  * Risk Factor: Blood pressure, greater than or equal to 130 / greater than or equal to 85 mmHg~  * Risk Factor: Fasting glucose, greater than or equal to 110 mg/dL~6. Fasting blood glucose \>60 mg/dL at screening~7. Willingness to allow sample storage for future research~8. Able to provide informed consent~EXCLUSION CRITERIA:~1. Established diagnosis of diabetes mellitus use of anti-diabetes medications, or a hemoglobin A1C (HgbA1C) of \>7.0%~2. History of eating disorder, uncontrolled mood or thought disorder, significant gastrointestinal disorder or malabsorption, or significant hepatic or renal impairment~3. Current use of medical therapy for overweight/obesity including phentermine, orlistat, lorcaserin, naltrexone/bupropion, and liraglutide or history of weight loss surgery. Concomitant use of medications with side effects known to potentially influence appetite are allowed if on a stable dose for at least 12 months~4. History of symptomatic hypoglycemia.~5. Use of systemic glucocorticoids (stable dose daily inhaled corticosteroid allowed)~6. Chronic viral hepatitis C; subjects with a history of hepatitis C successfully treated can enroll \>12 months after sustained virologic response~7. Alcohol or substance use disorder in the past year as defined by Diagnostic and Statistical Manual (DSM)-V or positive urine drug screen~8. Current pregnancy, actively seeking to become pregnant or breastfeeding~9. Any serious health or other condition which, in the opinion of the PI or their designee, could potentially interfere with the ability of a subject to comply with the procedures and assessments of the protocol or to safely participate and complete the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Intermittent Fasting diet (Type: EXPERIMENTAL): HIV positive subjects with body mass index ≥30 kg/m2 (obese) consume approximately 25% of their daily calories for 2 non-consecutive days per week, normal diet for the other 5 days, and receive healthy lifestyle counseling for 12 weeks.
- Standard of Care diet (Type: ACTIVE_COMPARATOR): HIV positive subjects with body mass index ≥30 kg/m2 (obese) receive nutritional and healthy lifestyle counseling for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues